NHS cancer drugs pass through NICE appraisal, which weighs clinical benefit against cost; the Cancer Drugs Fund gives interim access while evidence builds. Gaps remain: drugs licensed in the UK but not yet appraised, not recommended, or approved for a different cancer. Comprehensive private cancer cover typically pays for licensed drugs your specialist recommends, whether or not the NHS routinely funds them.
- ✓NICE appraises cancer drugs for clinical benefit and value; the CDF funds promising drugs while evidence builds.
- ✓Gaps exist: licensed-but-not-appraised drugs, negative recommendations, and off-indication uses.
- ✓Good private cancer cover pays for licensed drugs a specialist recommends, beyond NHS routine funding.
How a cancer drug reaches NHS patients
A cancer drug reaches NHS patients through a staged pipeline, and each stage does a different job. In general terms:
- Licensing. The MHRA licenses a drug as safe and effective for a specific use. Licensing means it can be prescribed in the UK — not that the NHS will pay for it.
- NICE appraisal. NICE weighs the drug's clinical benefit against its cost, usually per quality-adjusted life year. A positive recommendation obliges the NHS in England to fund it, normally within three months.
- The Cancer Drugs Fund (CDF). When a drug looks promising but the evidence is still uncertain, NICE can route it into the CDF: patients get access now, while real-world data is collected, and the drug is re-appraised later — moving to routine funding or exiting.
- Routine commissioning. The end state: the drug is a standard NHS treatment option for its approved indication.
It's worth saying clearly: this system works well for most patients, most of the time. The majority of clinically important cancer drugs are NHS-funded, and the CDF has meaningfully sped up access since its 2016 reform.
Where the gaps appear
The gaps are real but specific. They tend to fall into three categories.
| The gap | What it means for a patient |
|---|---|
| Licensed, not yet appraised | A drug is legally prescribable in the UK but NICE hasn't finished (or started) its appraisal, so the NHS doesn't routinely fund it yet |
| Appraised, not recommended | NICE judged the price too high for the benefit shown. The drug may still be clinically reasonable for some patients — at private cost |
| Licensed for a different cancer | A drug funded for one indication may show promise in another; NHS funding generally follows the appraised indication |
In each case the drug exists, is licensed for UK use in at least one setting, and a specialist might reasonably want to prescribe it — but the NHS route is closed or delayed. That, precisely, is the territory private cancer cover addresses.
What private cancer cover changes
Comprehensive private medical insurance with full cancer cover typically pays for licensed cancer drugs that your consultant oncologist recommends — including drugs the NHS doesn't routinely fund, provided they're licensed and evidence-based. Insurers vary in the detail, but the strongest policies cover the drug bill for as long as treatment is clinically appropriate.
Private cover also typically means faster access at each step — consultation within days rather than weeks, and no wait for an appraisal timeline to conclude. What it doesn't do is unlock unlicensed or experimental treatments: insurers generally require a UK licence and recognised evidence, much as the NHS does.
Compare cancer cover properly
Keeping it in proportion
Cancer drug access is an area where fear sells, so let's be measured. If you're treated on the NHS, you will get evidence-based cancer care, and for most cancers the drug list is the same one a private oncologist would use. The private difference shows up at the margins — newer drugs in the appraisal pipeline, negative NICE decisions, off-indication use — and in speed and continuity.
And remember the standing exclusion: if you've had cancer before taking out a policy, it will generally be excluded as pre-existing. Private cancer cover is protection you buy while well.
Frequently asked questions
What is the Cancer Drugs Fund and how does it work?
The CDF is an NHS England fund that gives patients interim access to promising cancer drugs while evidence on their effectiveness is still building. NICE routes drugs into the fund at appraisal, real-world data is collected, and the drug is later re-appraised — moving into routine NHS funding or exiting the fund.
Why are some cancer drugs not available on the NHS?
Usually one of three reasons: NICE hasn't yet completed its appraisal, NICE judged the price too high for the demonstrated benefit, or the drug is licensed for a different cancer than yours. The drug may still be legally prescribable in the UK — but privately funded rather than NHS-funded.
Does private health insurance pay for cancer drugs the NHS won't fund?
Comprehensive policies with full cancer cover typically do, provided the drug is UK-licensed and recommended by your consultant oncologist. Cover terms vary significantly between insurers — some pay drug costs for as long as clinically appropriate, others apply limits — so compare the cancer section of policies carefully.
Will private cancer cover pay for experimental or unlicensed drugs?
Generally, no. Insurers usually require a UK licence and recognised clinical evidence, much like the NHS. The private advantage lies with licensed drugs that sit outside routine NHS funding — awaiting appraisal, declined on cost grounds, or used beyond their appraised indication — not with experimental treatment.
Can I get cancer drug cover if I've already had cancer?
Almost never for that cancer. Standard UK health insurance excludes pre-existing conditions, and a previous cancer diagnosis is typically excluded at underwriting — sometimes with related conditions too. Some insurers reconsider after long claim-free periods. Cancer cover is fundamentally a product you buy while healthy.